Financial Performance - Revenue increased by RMB 781.5 million or 15.0% to RMB 5,981.7 million compared to the year ended December 31, 2021[2] - EBITDA rose by RMB 905.9 million or 99.9% to RMB 1,812.8 million, while normalized EBITDA increased by RMB 607.3 million or 44.8% to RMB 1,962.6 million[2] - Gross profit increased by RMB 743.8 million or 21.9% to RMB 4,140.5 million, with a gross profit margin of 69.2%[2] - Net profit attributable to shareholders was RMB 604.8 million, an increase of RMB 739.2 million compared to a net loss in the previous year[2] - Total comprehensive income for the year was RMB 576.9 million, compared to a loss of RMB 168.9 million in the previous year[6] - Basic earnings per share were RMB 17.38, compared to a loss of RMB 3.90 per share in the previous year[5] Revenue Breakdown - The revenue from product sales was RMB 5,059,298,000, with significant contributions from various therapeutic areas including cardiovascular and oncology[18] - Revenue in the oncology treatment sector increased by 63.1% to RMB 2,305.8 million in 2022[53] - Cardiovascular treatment revenue rose by 7.6% to RMB 1,535.7 million, while central nervous system treatment revenue decreased by 0.1% to RMB 1,322.7 million[53] - The sales revenue from digestive and metabolic products decreased to RMB 632.4 million, a decline of approximately RMB 266.1 million or 29.6% compared to RMB 898.5 million in the previous year[90] Expenses and Costs - Research and development expenses increased by RMB 174.2 million or 25.5% to RMB 857.3 million, with total R&D expenses amounting to RMB 1,399.4 million[2] - Administrative expenses for the year were RMB 582,870,000, while other expenses totaled RMB 990,405,000[18] - Financial costs rose to RMB 471,755 thousand in 2022 from RMB 399,458 thousand in 2021, marking an increase of about 18.1%[31] - Total tax expense for the year was RMB 86,466 thousand, compared to RMB 70,226 thousand in 2021, indicating an increase of approximately 23.1%[34] Assets and Liabilities - Non-current assets increased to RMB 13,463,812 thousand in 2022 from RMB 12,185,397 thousand in 2021, representing an increase of approximately 10.5%[8] - Current assets totaled RMB 10,785,813 thousand in 2022, up from RMB 10,396,664 thousand in 2021, reflecting a growth of about 3.7%[8] - Total liabilities rose to RMB 13,207,903 thousand in 2022, compared to RMB 13,468,158 thousand in 2021, indicating a decrease of approximately 1.9%[9] - The company's net assets increased to RMB 11,041,722 thousand in 2022, up from RMB 9,113,903 thousand in 2021, marking a growth of around 21.1%[10] Shareholder Returns - The board did not recommend the declaration of any dividend for the year ended December 31, 2022[5] - No interim or final dividends were declared for the year ended December 31, 2022, consistent with 2021[36] Market and Product Development - The company is investing in four strategic therapeutic areas: oncology, central nervous system, cardiovascular, and digestive and metabolic diseases, with 35 products in various stages of development in China[65] - The company has eight products under NDA review in various markets, with five products undergoing NDA review in mainland China[88] - The newly launched product, Bo You Bei, is the world's first approved biosimilar of Prolia for treating osteoporosis in postmenopausal women, significantly reducing fracture risks[87] Compliance and Governance - The company has complied with all applicable corporate governance codes as of December 31, 2022, with one exception regarding the roles of the chairman and CEO[111] - The company has confirmed compliance with the standard code of conduct for securities trading by all directors for the year ending December 31, 2022[112]
绿叶制药(02186) - 2022 - 年度业绩